Document:

Amendment to Securities Purchase Agreement and Related Documents

 Exhibit 10.2 
  
 AMENDMENT 
 TO

 SECURITIES PURCHASE AGREEMENT 
 AND RELATED DOCUMENTS 
  
 This AMENDMENT (this
“Amendment”) is entered into by and between TRANSGENOMIC, INC., a Delaware corporation (the “Company”), and LAURUS MASTER FUND, LTD., a Cayman Islands company (“Laurus”) as of August 31, 2004, for
the purpose of further amending the terms of (i) the Securities Purchase Agreement, dated February 19, 2004 and previously amended on April 15, 2004, by and between the Company and Laurus (the ”Securities Purchase Agreement”), the
Secured Convertible Term Note, dated February 19, 2004 and previously amended on April 15, 2004 (the ”Term Note”) issued by the Company pursuant to the Securities Purchase Agreement, and the Registration Rights Agreement, dated
February 19, 2004 (the ”Registration Rights Agreement”) (collectively, the ”Term Loan Documents”). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Securities
Purchase Agreement. 
  
 WHEREAS, the Company and Laurus have
agreed to make certain changes to the Term Loan Documents as set forth herein; 
  
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	The definition of “Fixed Conversion Price” set forth in the Term Note is hereby amended to mean $1.00 per share. 

  

	 	2.	Notwithstanding anything to the contrary contained in the Term Note, in the event that the closing price of the Company’s common stock equals or exceeds $1.75 per share for any
day (as such share price is adjusted for any combination, subdivision, stock split, dividend, distribution or similar event which results in a greater or smaller number of shares of common stock of the Company), the Interest Rate (as defined in the
Term Note) for such day shall be reduced to 0% (it being understood that in the event that the closing price of the Company’s common stock is less than $1.75 per share for any day following such a reduction referred to above in this Section 2,
the Interest Rate for such day shall be calculated in accordance with the Term Note without giving effect to this Section 2). 

  

	 	3.	The amortization table set forth in Section 1.2 of the Term Note is hereby deleted in its entirety and the following new amortization table is hereby inserted in Section 1.2 of the
Term Note in lieu thereof: 

							
	 Date

	 	 Principal Amount

	 	 Date

	 	 Principal Amount

				
	 	 	 	 	9/1/05	 	$75,000
				
	 	 	 	 	10/1/05	 	$75,000
				
	 	 	 	 	11/1/05	 	$75,000
				
	 9/1/04
	 	$0	 	12/1/05	 	$75,000
				
	 10/1/04
	 	$0	 	1/1/06	 	$75,000
				
	 11/1/04
	 	$0	 	2/1/06	 	$75,000
				
	 12/1/04
	 	$50,000	 	3/1/06	 	$75,000
				
	 1/1/05
	 	$50,000	 	4/1/06	 	$75,000
				
	 2/1/05
	 	$50,000	 	5/1/06	 	$75,000
				
	 3/1/05
	 	$75,000	 	6/1/06	 	$75,000
				
	 4/1/05
	 	$75,000	 	7/1/06	 	$75,000
				
	 5/1/05
	 	$75,000	 	8/1/06	 	$75,000
				
	 6/1/05
	 	$75,000	 	9/1/06	 	$75,000
				
	 7/1/05
	 	$75,000	 	10/1/06	 	$75,000
				
	 8/1/05
	 	$75,000	 	11/1/06	 	$75,000
				
	 	 	 	 	12/1/06	 	$75,000
				
	 \
	 	 	 	1/1/07	 	$125,000
				
	 	 	 	 	2/1/07	 	$125,000
				
	 	 	 	 	2/19/07	 	$700,000

  
 4. The Company hereby
agrees to, on or prior to September 13, 2004, file a registration statement under the Securities Act of 1933, as amended, relating to all shares that may be issued by it upon conversion of borrowings under the Term Note, as well as under that
certain Secured Minimum Borrowing Note, Series B, dated December 3, 2003 (the ”Minimum Borrowing Note”), and any warrants related to either such transactions, to ensure that a sufficient number of shares of Common Stock of the
Company are registered under such Registration Statement, assuming (x) the full conversion of each of the Term Note (after giving effect to the adjustments to the Fixed Conversion Price as set forth in Section 1 above), the Minimum Borrowing Note
(based on any amendments made to the conversion price thereof) and (y) the complete exercise of the additional warrant issued by the Company to Laurus in connection with the amendment to the Minimum Borrowing Note (the “Registration
Statement”). 
  
 5. Laurus and the Company hereby agree
that as promptly as practicable following the declaration by the Securities and Exchange Commission that the Registration Statement is effective, Laurus shall convert into Common Stock of the Company (x) interest that has accrued prior to August 1,
2004 under the Term Note (the ”Accrued Interest Amount”) and (y) a principal amount under the Term Note in an amount equal to $150,000 (which converted amount, following such a conversion, shall be applied to reduce the amortization
payment to be made by the Company on February 19, 2007 to $550,000). Laurus and the Company agree that the Accrued Interest Amount shall only become payable in cash on the Maturity Date (as defined in the Term Note) in the event that the Accrued
Interest Amount has not been converted into Common Stock of the Company in accordance with the immediately preceding sentence prior to the Maturity Date. 
  
 6. Laurus hereby acknowledges that no Event of Default has occurred with respect to the payment of principal or interest under any of the Term Loan
Documents prior to the date hereof. 
  
 7. As long as no Event of
Default exist under any of the Term Loan Documents, Laurus agrees that it shall not require any further amendment, modification or waiver by the Company of any of the terms of the Term Loan Documents in connection with obtaining the consent of
Laurus to the sale of any or all of the assets associated with the Company’s synthetic nucleic acid operations in Boulder, Colorado, and Laurus agrees that such consent shall not be unreasonably withheld. 
  
 8. This Amendment to the Term Loan Documents shall be effective as of the
date hereof following the execution of same by each of the Company and the Laurus. 
  
 9. Except as specifically set forth in this Amendment, there are no other amendments to the Term Loan Documents, and all of the other forms, terms and provisions of the Term Loan Documents remain in full force and
effect, including, specifically, each of those provisions of the Term Loan Documents that limit the total number of shares of stock that the Company will issue thereunder at a price of less than $2.65 per share to 5,776,614. 

 10.    The Company hereby represents and warrants to Laurus that as of the date
hereof all representations, warranties and covenants made by Company in connection with the Term Loan Documents are true, correct and complete and all of Company’s covenant requirements have been met. 
  
 11.    This Amendment shall be binding upon the parties
hereto and their respective successors and permitted assigns and shall inure to the benefit of and be enforceable by each of the parties hereto and its successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE
WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. 
  
 IN WITNESS WHEREOF, each of the Company and Laurus has caused this
Amendment to the Revolving Loan Documents to be signed in its name effective as of this 31st day of August, 2004. 
  

			
	TRANSGENOMIC, INC.
		
	By:	 	 
	 	 	 Name:
 Title:

  

			
	LAURUS MASTER FUND, LTD.
		
	By:	 	 
	 	 	 Name:
 Title:Common Stock Purchase Warrant

 Exhibit 10.3 
  
 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO TRANSGENOMIC, INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 Right to Purchase 400,000 Shares of Common 
 Stock of Transgenomic, Inc. (subject to adjustment 
 as provided herein) 
  
 COMMON STOCK PURCHASE WARRANT 
  
 No. 
 Issue Date: August 31, 2004

  
 Transgenomic, Inc., a corporation organized under the laws of
the State of Delaware (the “Company”), hereby certifies that, for value received, LAURUS MASTER FUND, LTD., or assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company from and after
the Issue Date of this Warrant and at any time or from time to time before 5:00 p.m., New York time, through seven (7) years after such date (the “Expiration Date”), up to 400,000 fully paid and nonassessable shares of Common Stock (as
hereinafter defined), $.01 par value, of the Company, at the Exercise Price (as defined below). The number and character of such shares of Common Stock and the Exercise Price are subject to adjustment as provided herein. 
  
 These Warrants are being issued in connection with certain amendments made as
of the date hereof to the certain (i) the Security Agreement, dated December 3, 2003 and previously amended on February 20 and April 15, 2004, by and between the Company and Laurus (the ”Security Agreement”), (ii) the Secured Convertible
Minimum Borrowing Note Series B, dated December 3, 2003 and previously amended on April 15, 2004 (the ”Minimum Borrowing Note”) issued by the Company pursuant to the Security Agreement, (iii) the Secured Revolving Note, dated December 3,
2003 and previously amended on April 15, 2004 (the ”Revolving Note”) issued by the Company pursuant to the Security Agreement (collectively, the “Revolving Loan Documents”). As used herein the following terms, unless the context
otherwise requires, have the following respective meanings: 
  
 (a) The term “Company” shall include Transgenomic, Inc. and any corporation which shall succeed or assume the obligations of Transgenomic, Inc. hereunder. 
  
 (b) The term “Common Stock” includes (a) the
Company’s Common Stock, par value $.01 per share, and (b) any other securities into which or for which any of the securities described in (a) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of
assets or otherwise. 
  

 (c) The term “Other Securities” refers to any stock (other than Common Stock)
and other securities of the Company or any other person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant, in lieu of or in addition to Common
Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise. 
  
 (d) The term “Exercise Price” shall be as follows: 
  
 a. 400,000 shares at $1.25 per share; 
  
 2. Exercise of Warrant. 
  
 2.1 Number of Shares Issuable upon Exercise. From and after the date
hereof through and including the Expiration Date, the Holder shall be entitled to receive, upon exercise of this Warrant in whole or in part, by delivery of an original or fax copy of the exercise notice attached hereto as Exhibit A (the
“Exercise Notice”), shares of Common Stock of the Company, subject to adjustment pursuant to Section 4. Notwithstanding anything contained herein to the contrary, the Holder shall not be entitled to exercise this Warrant on an exercise
date, in connection with that number of Shares which, when added to the number of shares of Common Stock otherwise beneficially owned by such Holder including those issuable upon exercise of warrants held by such Holder would exceed 4.99% of the
outstanding shares of Common Stock of the Company at the time of conversion. For the purposes of the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and Regulation 13d-3
thereunder. The limitation described in this section shall automatically become null and void without any notice to Borrower upon the occurrence and during the continuance beyond any applicable grace period of an event of default under any borrowing
agreement between the Company and the Holder, or upon 75 days prior notice to the Company. Notwithstanding anything contained herein to the contrary, the number of shares of Common Stock issuable by the Borrower and acquirable by the Holder at a
price below $1.80 per share pursuant to the terms of the Minimum Borrowing Notes, Revolving Note and/or other warrants issued by the Borrower to the Holder pursuant to the Revolving Loan Documents, shall not exceed an aggregate of 5,595,705 shares
of the Borrower’s Common Stock, (subject to appropriate adjustment for stock splits, stock dividends, or other similar recapitalizations affecting the Common Stock) (the “Maximum Common Stock Issuance”), unless the issuance of shares
hereunder in excess of the Maximum Common Stock Issuance shall first be approved by the Borrower’s shareholders. If at any point in time and from time to time the number of shares of Common Stock issued pursuant to the terms of the Revolving
Loan Documents, together with the number of shares of Common Stock that would then be issuable by the Borrower to the Holder in the event of the exercise of this Warrant, would exceed the Maximum Common Stock Issuance but for this section, the
Borrower shall promptly call a shareholders meeting to solicit shareholder approval for the issuance of the shares of Common Stock hereunder in excess of the Maximum Common Stock Issuance. 
  
 2.2 Fair Market Value. Fair Market Value of a share of Common Stock as
of a particular date (the “Determination Date”) shall mean: 
  

 2 

 (a) If the Company’s Common Stock is traded on an exchange or is quoted on the
National or SmallCap Market of The Nasdaq Stock Market, Inc. (“Nasdaq”), then the closing or last sale price, respectively, reported for the last business day immediately preceding the Determination Date. 
  
 (b) If the Company’s Common Stock is not traded on an
exchange or on the Nasdaq but is traded on the NASD OTC Bulletin Board or BBX Exchange, then the mean of the average of the closing bid and asked prices reported for the last business day immediately preceding the Determination Date. 
  
 (c) Except as provided in clause (d) below, if the
Company’s Common Stock is not publicly traded, then as the Holder and the Company agree or in the absence of agreement by arbitration in accordance with the rules then in effect of the American Arbitration Association, before a single
arbitrator to be chosen from a panel of persons qualified by education and training to pass on the matter to be decided. 
  
 (d) If the Determination Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation,
dissolution or winding up pursuant to the Company’s charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the charter in the event of such liquidation, dissolution or winding up, plus all other amounts to
be payable per share in respect of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all of the shares of Common Stock then issuable upon exercise of the Warrant are outstanding at the Determination
Date. 
  
 3. Procedure for Exercise. 
  
 3.1 Delivery of Stock Certificates, etc. on Exercise. The Company
agrees that the shares of Common Stock purchased upon exercise of this Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered
and payment made for such shares as aforesaid. As soon as practicable after the exercise of this Warrant in full or in part, and in any event within 3 business days thereafter, the Company at its expense (including the payment by it of any
applicable issue taxes) will cause to be issued in the name of and delivered to the Holder, or as such Holder (upon payment by such holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or
certificates for the number of duly and validly issued, fully paid and nonassessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus, in lieu of any fractional share to which such holder
would otherwise be entitled, cash equal to such fraction multiplied by the then Fair Market Value of one full share, together with any other stock or other securities and property (including cash, where applicable) to which such Holder is entitled
upon such exercise pursuant to Section 1 or otherwise. 
  
 3.2
Exercise. 
  
 (a) Payment may be made
either in (i) cash or by certified or official bank check payable to the order of the Company equal to the applicable aggregate Exercise Price, (ii) by delivery of the Warrant, Common Stock and/or Common Stock receivable upon exercise of 

 

 3 

 the Warrant in accordance with Section (b) below, or (iii) by a combination of any of the foregoing methods, for the
number of Common Shares specified in such form (as such exercise number shall be adjusted to reflect any adjustment in the total number of shares of Common Stock issuable to the holder per the terms of this Warrant) and the Holder shall thereupon be
entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock (or Other Securities) determined as provided herein. 
  
 (b) Notwithstanding any provisions herein to the contrary, if the Fair Market Value of one share of Common Stock is greater
than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being
exercised) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Exercise Notice in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following
formula: 
  

	 	X=Y	(A-B) 

 A 
  
 Where X = the number of shares of Common Stock to be issued
to the Holder 
  

	 	Y=	the number of shares of Common Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised (at the date
of such calculation) 

  

	 	A=	the Fair Market Value of one share of the Company’s Common Stock (at the date of such calculation) 

  

	 	B=	Exercise Price (as adjusted to the date of such calculation) 

  
 4. Effect of Reorganization, etc.; Adjustment of Exercise Price. 
  
 4.1 Reorganization, Consolidation, Merger, etc. In case at any time or from time to time, the Company shall (a)
effect a reorganization, (b) consolidate with or merge into any other person, or (c) transfer all or substantially all of its properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then,
in each such case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made by the Company whereby the Holder of this Warrant, on the exercise hereof as provided in Section 1 at any time after the
consummation of such reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall receive, in lieu of the Common Stock (or Other Securities) issuable on such exercise prior to such consummation or such
effective date, the stock and other securities and property (including cash) to which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had so exercised this
Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided in Section 4. 
  
 4.2 Dissolution. In the event of any dissolution of the Company following the transfer of all or substantially all of its properties or assets, the
Company, prior to such dissolution, shall at its expense deliver or cause to be delivered the stock and other securities and 
  

 4 

 property (including cash, where applicable) receivable by the Holder of the Warrant after the effective date of such
dissolution pursuant to Section 3.1 to a bank or trust company having its principal office in New York, NY, as trustee for the Holder of the Warrant. 
  
 4.3 Continuation of Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred to in
this Section 4, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation of such
reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer of any such stock or other securities, including, in the case of any such transfer,
the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant as provided in Section 5. In the event this Warrant does not continue in full
force and effect after the consummation of the transactions described in this Section 4, then only in such event will the Company’s securities and property (including cash, where applicable) receivable by the holders of the Warrant be delivered
to the Trustee as contemplated by Section 4.2. 
  
 5.   Extraordinary Events Regarding Common Stock. 
  
 5.1 Reclassification, etc. If the Company at any time shall, by reclassification or otherwise, change the Common Stock into the same or a different number of securities of any class or classes, this Warrant
shall thereafter be deemed to evidence the right to be issued an adjusted number of such securities and kind of securities as would have been issuable as the result of such change with respect to the Common Stock immediately prior to such
reclassification or other change. 
  
 5.2 Stock Splits,
Combinations and Dividends. If the shares of Common Stock are subdivided or combined into a greater or smaller number of shares of Common Stock, or if a dividend is paid on the Common Stock in shares of Common Stock, the Exercise Price shall be
proportionately reduced in case of subdivision of shares or stock dividend or proportionately increased in the case of combination of shares, in each such case by the ratio which the total number of shares of Common Stock outstanding immediately
after such event bears to the total number of shares of Common Stock outstanding immediately prior to such event. 
  
 5.3 Share Issuances. Subject to the provisions of this Section, if the Company shall at any time issue any shares of Common Stock to a person other
than the Holder (except (a) pursuant to Sections 5.1 or 5.2 above; (b) pursuant to options, warrants, or other obligations to issue shares outstanding on the date hereof as disclosed to Holder in writing; or (c) pursuant to options that may be
issued under any employee incentive stock option and/or any qualified stock option plan adopted by the Company) for a consideration per share (the “Offer Price”) less than the Exercise Price in effect at the time of such issuance, then the
Exercise Price shall be immediately reset pursuant to the formula below. For purposes hereof, the issuance of any security of the Company convertible into or exercisable or exchangeable for Common Stock shall result in an adjustment to the Exercise
Price at the time of issuance of such securities. If the Company issues any additional shares pursuant to this Section then, and thereafter successively 
  

 5 

 upon each such issue, the Exercise Price shall be adjusted by multiplying the then applicable Exercise Price by the
following fraction: 
  

	
	A + B
	(A + B) + [((C - D) x B) / C]

  
 A = Actual shares
outstanding prior to such offering 
 B = Actual shares sold in the offering 
 C = Exercise Price 
 D = Offering price 
  
 5.4 Computation of Consideration. For purposes of any computation
respecting consideration received pursuant to Section 5.3 above, the following shall apply: 
  
 (a) In the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash, provided that in
no case shall any deduction be made for any commissions, discounts or other expenses incurred by the Company for any underwriting of the issue or otherwise in connection therewith; 
  
 (b) In the case of the issuance of shares of Common Stock for a consideration in whole or in part other than
cash, the consideration other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Board of Directors of the Company (irrespective of the accounting treatment thereof); and 
  
 (c) Upon any such exercise, the aggregate consideration
received for such securities shall be deemed to be the consideration received by the Company for the issuance of such securities plus the additional minimum consideration, if any, to be received by the Company upon the conversion or exchange thereof
(the consideration in each case to be determined in the same manner as provided in clauses (a) and (b) of this Section 5.4). 
  
 6. In the event that the Company shall (a) issue additional shares of the Common Stock as a dividend or other distribution on outstanding Common Stock,
(b) subdivide its outstanding shares of Common Stock, (c) combine its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock or (d) issue any shares of Common Stock to a Person other than the Holder (other than
(i) pursuant to Subsections (a), (b) or (c) above or (ii) pursuant to options, warrants or other obligations to issue shares outstanding on the date hereof or (iii) any shares issued for incentive stock options or NonQualified stock options in each
case under the Company’s Employee Stock Option Plan) for a consideration per share or having an exercise, conversion or exchange price less than the Exercise Price in effect at the time of such issuance, then, in each such event, the Exercise
Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the
denominator of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be readjusted
in the same manner upon the happening of any successive event or events described herein in this 
  

 6 

 
Section 4. The number of shares of Common Stock that the holder of this Warrant shall thereafter, on the exercise hereof as provided in Section 1, be
entitled to receive shall be increased to a number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this Section 4) be issuable on such exercise by a fraction of which (a) the numerator
is the Exercise Price that would otherwise (but for the provisions of this Section 4) be in effect, and (b) the denominator is the Exercise Price in effect on the date of such exercise. 
  
 7. Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock (or
Other Securities) issuable on the exercise of the Warrant, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of the
Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable by the Company
for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price
and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy
of each such certificate to the holder of the Warrant and any Warrant agent of the Company (appointed pursuant to Section 11 hereof). 
  
 8. Reservation of Stock, etc. Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely for issuance and
delivery on the exercise of the Warrant, shares of Common Stock (or Other Securities) from time to time issuable on the exercise of the Warrant. 
  
 9. Assignment; Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be
transferred by any registered holder hereof (a “Transferor”) with respect to any or all of the Shares. On the surrender for exchange of this Warrant, with the Transferor’s endorsement in the form of Exhibit B attached hereto (the
“Transferor Endorsement Form”) and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, which shall include, without limitation, a legal opinion from the Transferor’s
counsel that such transfer is exempt from the registration requirements of applicable securities laws, the Company at its expense) but with payment by the Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the
Transferor thereof a new Warrant of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”), calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock called for on the face or faces of the Warrant so surrendered by the Transferor. 
  
 10. Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such 
  

 7 

 
mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

  
 11. Registration Rights. The Holder of this Warrant has
been granted certain registration rights by the Company. These registration rights are set forth in a Registration Rights Agreement entered into by the Company and Purchaser of the Company’s Convertible Note (the “Note”) at or prior
to the issue date of this Warrant. 
  
 12. Maximum
Exercise. The Holder shall not be entitled to exercise this Warrant on an exercise date, in connection with that number of shares of Common Stock which, when added to (i) the number of shares of Common Stock otherwise beneficially owned by the
Holder and its affiliates on an exercise date, and (ii) the number of shares of Common Stock issuable upon the exercise of this Warrant with respect to which the determination of this proviso is being made on an exercise date, would result in
beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock of the Company on such date. For the purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be
determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. Subject to the foregoing, the Holder shall not be limited to aggregate exercises which would result in the issuance of
more than 4.99%. The restriction described in this paragraph may be revoked upon 75 days prior notice from the Holder to the Company and is automatically null and void upon an Event of Default under the Note. 
  
 13. Warrant Agent. The Company may, by written notice to the each
holder of the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 1, exchanging this Warrant pursuant to Section 7, and replacing this Warrant pursuant to
Section 8, or any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by such agent. 
  

14. Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may treat the registered
holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
  
 15. Notices, etc. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class registered or
certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such holder or, until any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder of this Warrant who
has so furnished an address to the Company. 
  
 16. Voluntary
Adjustment by the Company. The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. 
  
 17. Miscellaneous. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant shall be governed by and construed in accordance with the laws
of State of New York without regard to 
  

 8 

 
principles of conflicts of laws. Any action brought concerning the transactions contemplated by this Warrant shall be brought only in the state courts of New
York or in the federal courts located in the state of New York; provided, however, that the Holder may choose to waive this provision and bring an action outside the state of New York. The individuals executing this Warrant on behalf of the Company
agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Warrant is
invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The headings in this Warrant are for purposes of reference only, and shall not limit or
otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. The Company acknowledges that legal counsel participated in the
preparation of this Warrant and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Warrant to favor any party against the other
party. 
  
 IN WITNESS WHEREOF, the Company has executed this
Warrant under seal as of the date first written above. 
  

			
	TRANSGENOMIC, INC.
		
	By:	 	 
	 	 	 Name:
 Title:

  

			
	Witness:
	
	 
	 	 	 

  
  

 9 

 Exhibit A 
  

FORM OF SUBSCRIPTION 
  
 (To be signed only on exercise of Warrant) 
  
 TO: Transgenomic, Inc. 
  
 The undersigned, pursuant to the provisions set forth in the attached Warrant (No.            ), hereby irrevocably elects to purchase (check
applicable box): 
  

	 ̈	             shares of the Common Stock covered by such Warrant; or 

  

	 ̈	the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in Section 2. 

  
 The undersigned herewith makes payment of the full Exercise Price for such shares at the
price per share provided for in such Warrant, which is $            . Such payment takes the form of (check applicable box or boxes): 
  

	 ̈	$             in lawful money of the United States; and/or 

  

	 ̈	the cancellation of such portion of the attached Warrant as is exercisable for a total of              shares of
Common Stock (using a Fair Market Value of $             per share for purposes of this calculation); and/or 

  

	 ̈	the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 2, to exercise this Warrant with respect to the
maximum number of shares of Common Stock purchaseable pursuant to the cashless exercise procedure set forth in Section 2. 

  
 The undersigned requests that the certificates for such shares be issued in the name of, and delivered to
                                     whose address is
                                        
    . 
  
 The undersigned represents and warrants that all
offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”) or pursuant
to an exemption from registration under the Securities Act. 
  

					
	Dated:                                   
 	 	 	 	 
	  	 	 	 	 (Signature must conform to name of holder as specified on the face of the Warrant)
  
  

	 	 	 	 	(Address)

  

 Exhibit B 
  

FORM OF TRANSFEROR ENDORSEMENT 
 (To be
signed only on transfer of Warrant) 
  
 For value received, the
undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of Transgenomic,
Inc. to which the within Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,” respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its
respective right on the books of Transgenomic, Inc. with full power of substitution in the premises. 
  

					
	 Transferees
	 	Percentage Transferred	 	Number Transferred
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

  
  

					
	Dated:                                   
 	 	 	 	 
	  
  
 Signed in the presence of:
	 	 	 	 (Signature must conform to name of holder as specified on the face of the Warrant)
  
  

	(Name)	 	 	 	(address)
			
	 ACCEPTED AND AGREED: [TRANSFEREE]
  
  
	 	 	 	  
	(Name)	 	 	 	(address)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]